世界の神経変性薬市場 2019年

【英語タイトル】Global Neurodegenerative Drugs Market Professional Survey Report 2019

QYResearchが出版した調査資料(QYR20FB03815)・商品コード:QYR20FB03815
・発行会社(調査会社):QYResearch
・発行日:2019年10月(※2024年版があります。お問い合わせください)
・ページ数:104
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、神経変性薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、NMDA、SSRI、ドーパミン阻害剤に、用途別には、病院、研究にセグメント区分し、神経変性薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・神経変性薬の世界市場概要
・神経変性薬の製造コスト構成分析
・神経変性薬の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・神経変性薬の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・神経変性薬のセグメント分析(種類別)
(NMDA、SSRI、ドーパミン阻害剤)
・神経変性薬のセグメント分析(用途別)
(病院、研究)
・神経変性薬の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Novartis、Pfizer、Merck Serono、Biogen Idec、TEVA Pharmaceuticals、UCB、Boehringer Ingelheim、Sanofi、GlaxoSmithKline)
・神経変性薬の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Neurodegeneration is a broader term which comprises of different disease namely Parkinson’s disease, Huntington disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. These are the most commonly occurring diseases under the condition “Neurodegeneration”.
The global Neurodegenerative Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Neurodegenerative Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Neurodegenerative Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Neurodegenerative Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Neurodegenerative Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA Pharmaceuticals
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
NMDA
SSRIs
Dopamine Inhibitors

Segment by Application
Hospital
Research

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Neurodegenerative Drugs
1.1 Definition of Neurodegenerative Drugs
1.2 Neurodegenerative Drugs Segment by Type
1.2.1 Global Neurodegenerative Drugs Production Growth Rate Comparison by Types (2014-2025)
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Neurodegenerative Drugs Segment by Applications
1.3.1 Global Neurodegenerative Drugs Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Research
1.4 Global Neurodegenerative Drugs Overall Market
1.4.1 Global Neurodegenerative Drugs Revenue (2014-2025)
1.4.2 Global Neurodegenerative Drugs Production (2014-2025)
1.4.3 North America Neurodegenerative Drugs Status and Prospect (2014-2025)
1.4.4 Europe Neurodegenerative Drugs Status and Prospect (2014-2025)
1.4.5 China Neurodegenerative Drugs Status and Prospect (2014-2025)
1.4.6 Japan Neurodegenerative Drugs Status and Prospect (2014-2025)
1.4.7 Southeast Asia Neurodegenerative Drugs Status and Prospect (2014-2025)
1.4.8 India Neurodegenerative Drugs Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Neurodegenerative Drugs
2.3 Manufacturing Process Analysis of Neurodegenerative Drugs
2.4 Industry Chain Structure of Neurodegenerative Drugs

3 Development and Manufacturing Plants Analysis of Neurodegenerative Drugs
3.1 Capacity and Commercial Production Date
3.2 Global Neurodegenerative Drugs Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Neurodegenerative Drugs
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Neurodegenerative Drugs Production and Capacity Analysis
4.2 Neurodegenerative Drugs Revenue Analysis
4.3 Neurodegenerative Drugs Price Analysis
4.4 Market Concentration Degree

5 Neurodegenerative Drugs Regional Market Analysis
5.1 Neurodegenerative Drugs Production by Regions
5.1.1 Global Neurodegenerative Drugs Production by Regions
5.1.2 Global Neurodegenerative Drugs Revenue by Regions
5.2 Neurodegenerative Drugs Consumption by Regions
5.3 North America Neurodegenerative Drugs Market Analysis
5.3.1 North America Neurodegenerative Drugs Production
5.3.2 North America Neurodegenerative Drugs Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Neurodegenerative Drugs Import and Export
5.4 Europe Neurodegenerative Drugs Market Analysis
5.4.1 Europe Neurodegenerative Drugs Production
5.4.2 Europe Neurodegenerative Drugs Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Neurodegenerative Drugs Import and Export
5.5 China Neurodegenerative Drugs Market Analysis
5.5.1 China Neurodegenerative Drugs Production
5.5.2 China Neurodegenerative Drugs Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Neurodegenerative Drugs Import and Export
5.6 Japan Neurodegenerative Drugs Market Analysis
5.6.1 Japan Neurodegenerative Drugs Production
5.6.2 Japan Neurodegenerative Drugs Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Neurodegenerative Drugs Import and Export
5.7 Southeast Asia Neurodegenerative Drugs Market Analysis
5.7.1 Southeast Asia Neurodegenerative Drugs Production
5.7.2 Southeast Asia Neurodegenerative Drugs Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Neurodegenerative Drugs Import and Export
5.8 India Neurodegenerative Drugs Market Analysis
5.8.1 India Neurodegenerative Drugs Production
5.8.2 India Neurodegenerative Drugs Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Neurodegenerative Drugs Import and Export

6 Neurodegenerative Drugs Segment Market Analysis (by Type)
6.1 Global Neurodegenerative Drugs Production by Type
6.2 Global Neurodegenerative Drugs Revenue by Type
6.3 Neurodegenerative Drugs Price by Type

7 Neurodegenerative Drugs Segment Market Analysis (by Application)
7.1 Global Neurodegenerative Drugs Consumption by Application
7.2 Global Neurodegenerative Drugs Consumption Market Share by Application (2014-2019)

8 Neurodegenerative Drugs Major Manufacturers Analysis
8.1 Novartis
8.1.1 Novartis Neurodegenerative Drugs Production Sites and Area Served
8.1.2 Novartis Product Introduction, Application and Specification
8.1.3 Novartis Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Pfizer
8.2.1 Pfizer Neurodegenerative Drugs Production Sites and Area Served
8.2.2 Pfizer Product Introduction, Application and Specification
8.2.3 Pfizer Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Merck Serono
8.3.1 Merck Serono Neurodegenerative Drugs Production Sites and Area Served
8.3.2 Merck Serono Product Introduction, Application and Specification
8.3.3 Merck Serono Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Biogen Idec
8.4.1 Biogen Idec Neurodegenerative Drugs Production Sites and Area Served
8.4.2 Biogen Idec Product Introduction, Application and Specification
8.4.3 Biogen Idec Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 TEVA Pharmaceuticals
8.5.1 TEVA Pharmaceuticals Neurodegenerative Drugs Production Sites and Area Served
8.5.2 TEVA Pharmaceuticals Product Introduction, Application and Specification
8.5.3 TEVA Pharmaceuticals Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 UCB
8.6.1 UCB Neurodegenerative Drugs Production Sites and Area Served
8.6.2 UCB Product Introduction, Application and Specification
8.6.3 UCB Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Boehringer Ingelheim
8.7.1 Boehringer Ingelheim Neurodegenerative Drugs Production Sites and Area Served
8.7.2 Boehringer Ingelheim Product Introduction, Application and Specification
8.7.3 Boehringer Ingelheim Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Sanofi
8.8.1 Sanofi Neurodegenerative Drugs Production Sites and Area Served
8.8.2 Sanofi Product Introduction, Application and Specification
8.8.3 Sanofi Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
8.9 GlaxoSmithKline
8.9.1 GlaxoSmithKline Neurodegenerative Drugs Production Sites and Area Served
8.9.2 GlaxoSmithKline Product Introduction, Application and Specification
8.9.3 GlaxoSmithKline Neurodegenerative Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.9.4 Main Business and Markets Served

9 Development Trend of Analysis of Neurodegenerative Drugs Market
9.1 Global Neurodegenerative Drugs Market Trend Analysis
9.1.1 Global Neurodegenerative Drugs Market Size (Volume and Value) Forecast 2019-2025
9.2 Neurodegenerative Drugs Regional Market Trend
9.2.1 North America Neurodegenerative Drugs Forecast 2019-2025
9.2.2 Europe Neurodegenerative Drugs Forecast 2019-2025
9.2.3 China Neurodegenerative Drugs Forecast 2019-2025
9.2.4 Japan Neurodegenerative Drugs Forecast 2019-2025
9.2.5 Southeast Asia Neurodegenerative Drugs Forecast 2019-2025
9.2.6 India Neurodegenerative Drugs Forecast 2019-2025
9.3 Neurodegenerative Drugs Market Trend (Product Type)
9.4 Neurodegenerative Drugs Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Neurodegenerative Drugs Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer



【掲載企業】

Novartis、Pfizer、Merck Serono、Biogen Idec、TEVA Pharmaceuticals、UCB、Boehringer Ingelheim、Sanofi、GlaxoSmithKline

★調査レポート[世界の神経変性薬市場 2019年] (コード:QYR20FB03815)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の神経変性薬市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆